文献速递免疫规划传染病防控与疫情报告

炭疽疫苗与环丙沙星或多西环素联用的药物-疫苗相互作用Ⅱ期研究

Effect of Co-administration of the anthrax vaccine adsorbed, adjuvanted with ciprofloxacin or doxycycline on antibiotic pharmacokinetics and the vaccine immunogenicity: A phase 2 drug-vaccine interaction study.
PubMed 文献 · Vaccine · 2025-12-24

这项Ⅱ期开放标签研究将210名健康成人随机分配至环丙沙星加CYFENDUS疫苗组、多西环素加CYFENDUS疫苗组或单用CYFENDUS疫苗组,评估抗菌药物药代动力学与疫苗免疫原性。环丙沙星药代动力学终点达标,多西环素Cmax等效性未完全达标但AUC达标;疫苗免疫原性终点达标,联用不劣于单用。常见反应多为1-2级。

要点

  • 环丙沙星与CYFENDUS疫苗联用不影响其AUC和Cmax等效性。
  • 多西环素与疫苗联用时Cmax等效性未达标但AUC达标,影响可能可忽略。
  • 联用环丙沙星或多西环素不降低疫苗免疫原性,安全性可接受。

核心结论

  • CYFENDUS疫苗与环丙沙星或多西环素联用安全性可接受,未影响相关药代动力学和免疫原性参数。

研究设计与样本

  • Ⅱ期开放标签研究,健康成人18至45岁共210人随机分配至环丙沙星加疫苗组、多西环素加疫苗组或单用疫苗组。

主要发现

  • 环丙沙星药代动力学终点达标:AUC0-12h均值比90%CI为0.8895至1.0718,Cmax为0.8693至1.0838,均在0.80至1.25内。
  • 多西环素药代动力学终点未达标:AUC0-12h的90%CI为0.8187至1.0278在等效标准内,但Cmax的90%CI下限0.7841低于0.80。
  • 免疫原性终点达标:联用环丙沙星或多西环素组与单用疫苗组的TNA NF50几何均值比95%CI下限分别为0.78和0.81,均高于非劣效界值0.5。
  • 大多数征集性反应和不良事件严重程度为1级或2级。

临床怎么用

  • 疑似或确诊炭疽芽孢杆菌暴露后预防时,CYFENDUS疫苗可与环丙沙星或多西环素同时接种,无需因相互作用调整方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CYFENDUS® vaccine (Anthrax Vaccine Adsorbed, Adjuvanted) with the recommended antibacterial drugs is licensed for post-exposure prophylaxis (PEP) following suspected or confirmed Bacillus anthracis exposure. This pre-licensure study examined potential interaction of CYFENDUS vaccine with ciprofloxacin and doxycycline when administered concomitantly. METHODS: In this Phase 2, open-label study, healthy adult participants (18 to 45 years of age; n = 210) were randomized to receive either ciprofloxacin+CYFENDUS vaccine, doxycycline+CYFENDUS vaccine, or CYFENDUS vaccine only. Pharmacokinetic (PK) parameters of antibacterials such as steady-state maximum concentration (Cmax) and area under the curve from 0 to 12 h (AUC0-12h) were assessed. Immunogenicity of the vaccine was evaluated using 50 % neutralizing factor (NF50) values generated by toxin neutralizing antibody (TNA) assay. Solicited reactogenicity and adverse events (AEs) were collected for safety evaluation. RESULTS: The PK endpoint was met for ciprofloxacin. The vaccine had no effect on PK with 90 % confidence intervals (CIs) of the mean ratios for AUC0-12h [90 % CI: 0.8895,1.0718] and Cmax [90 % CI: 0.8693,1.0838] contained within the predefined equivalence criteria [0.80, 1.25]. The PK endpoint was not met for doxycycline, wherein the 90 % of the mean ratios for AUC0-12h [90 % CI: 0.8187,1.0278] was within the equivalence criteria, but the lower bound of the 90 % CI for Cmax [90 % CI: 0.7841,1.0271] was below the equivalence limits [0.80, 1.25]; this impact on Cmax may be negligible to the extent that doxycycline efficacy is correlated with AUC. The immunogenicity endpoint was met, wherein the lower bound 95 % CIs for geometric mean ratio of TNA NF50 for the vaccine with ciprofloxacin (0.78) or doxycycline (0.81) to vaccine alone were above the non-inferiority margin (0.5). Most solicited reactogenicities and AEs were Grade 1 or 2 in severity. CONCLUSIONS: CYFENDUS vaccination with or without ciprofloxacin or doxycycline had an acceptable safety profile and co-administration did not affect the relevant PK and immunogenicity parameters. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04067011.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Drobic B, Akintunde G, Kim J, et al. Effect of Co-administration of the anthrax vaccine adsorbed, adjuvanted with ciprofloxacin or doxycycline on antibiotic pharmacokinetics and the vaccine immunogenicity: A phase 2 drug-vaccine interaction study. Vaccine. 2025. PMID: 41447782. doi:10.1016/j.vaccine.2025.128135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。